Based on our extensive clinical trial, the Covid-19 medical solution SaliraVira® performs very effectively to improve symptoms, reduce viral load, reduce the duration of treatment, prevent hospitalization and prevent the death of Covid-19 patients. The ingredients have anti-viral, anti-inflammatory, immune-enhancing properties and improve symptoms. The available compounds make Saliravira® a potent and promising drug with remarkable SARS-COV2 antiviral properties.
For more information, please contact
Peter Ressalehi CEO, Mim Pharma AS
+47 98 10 10 10
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which rebased, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.